In osimertinib-resistant H1975 (H1975OR) NSCLC cells, 30 demonstrated robust proteasomal degradation of AKT3 and anti-tumor effects without affecting AKT1/2. This evidence concerns the gene AKT3 and non-small cell lung carcinoma.